Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPACT MS: Ocrelizumab in Newly Diagnosed Relapsing MS and CIS
NCT04466150Phase 4Active, not recruiting
- Sponsor
- University of California, San Francisco
- Start
- Aug 2020
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of ocrelizumab in multiple sclerosis (MS), clinically isolated syndrome (CIS), sponsored by University of California, San Francisco. Started Aug 2020; status: active, not recruiting.
02
Drugs
ocrelizumab
03
Conditions
multiple sclerosis (MS)clinically isolated syndrome (CIS)
Beyond the preview
Go deeper on NCT04466150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04466150.